• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

Geron Corp

NASDAQ:GERN

$1.42 $0.03 (2.16%)

REAL-TIME: Last trade at

Jump to this page for:

Related Resources

22 Biopharma Stocks With Breakout Potential in 2012

5/22/2012 by TheStreet.com

Stem Cell Hype Has Yet To Breed Profits

5/22/2012 by Seeking Alpha

Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New Patent System

5/9/2012 by Marketwire

Geron Narrows Loss on Lower Costs - Analyst Blog

5/3/2012 by NASDAQ

Geron Narrows Loss on Lower Costs - Analyst Blog

5/3/2012 by Zacks Investment Research

Geron Narrows Loss on Lower Costs

5/3/2012 by Zacks Equity Research Analyst Blog

Geron Corp (GERN) Tops Q1 EPS by 3c

5/2/2012 by StreetInsider.com

Geron reports Q1 EPS (15c), consensus (18c)

5/2/2012 by Theflyonthewall.com

Geron says Chief legal Officer resigns

5/1/2012 by Theflyonthewall.com

BioTime: Backed By Dubious Stock Promoters

4/26/2012 by Seeking Alpha

Weekly Stock Watch: April 23-27

4/23/2012 by Seeking Alpha

5 Stocks Under $10 Set to Spike Higher

4/20/2012 by TheStreet.com

Stem Cell Research: Which Companies Will Emerge As Frontrunners?

4/19/2012 by Seeking Alpha

Geron management to meet with Lazard Capital

4/17/2012 by Theflyonthewall.com

Drug Information Association to host a conference

4/16/2012 by Theflyonthewall.com

BioTime Is Running Out Of Time - Short-Sell Idea

4/11/2012 by Seeking Alpha

Geron receives USPTO patent for CNS-tumor treatment method

4/10/2012 by Theflyonthewall.com

Biotech Stocks Look to Benefit From JOBS Act

4/10/2012 by Marketwire

Neutral on Geron Corp.

4/2/2012 by Zacks Equity Research Analyst Blog

Neutral on Geron Corp. - Analyst Blog

4/2/2012 by Zacks Investment Research

American Association for Cancer Research to host annual meeting

4/2/2012 by Theflyonthewall.com

Geron Misses Estimates - Analyst Blog

3/9/2012 by Zacks Investment Research

Geron Misses Estimates

3/9/2012 by Zacks Equity Research Analyst Blog

Geron Corp (GERN) Posts Q4 Loss of 25c/Share, Misses by 5c

3/8/2012 by StreetInsider.com

Geron Corp: Why I Decided To Take A Flyer On This $2 Biotech Stock

2/27/2012 by Seeking Alpha

Breakthrough Cancer Treatments Helping Death Rates Fall

2/27/2012 by Marketwire

Researchers obtain human eggs from stem cells, NY Times says

2/27/2012 by Theflyonthewall.com

A Paradigm Shift Without A Clutch

2/26/2012 by Seeking Alpha

Groundbreaking Technology And Buyout Potential Has InVivo Therapeutics On The Move

2/15/2012 by Seeking Alpha

The InVivo Effect

2/14/2012 by Seeking Alpha

Pharmacyclics Is Flying, But There Are Reasons To Be Wary

2/13/2012 by Seeking Alpha

Geron management to meet with JP Morgan

2/9/2012 by Theflyonthewall.com

Geron: Mea Culpa

2/6/2012 by Seeking Alpha

Stem cell therapies could get lift from trial results, NY Times says

1/23/2012 by Theflyonthewall.com

ACT trumpets positive efficacy data from ESC trial sampling

1/23/2012 by Fierce Biotech

Bearish Bettors Eye Geron's Longer-Term Puts

1/20/2012 by Schaeffer's Daily Market Blog

Bearish Bettors Eye Geron's Longer-Term Puts

1/20/2012 by Schaeffer's Investment Research

More Biotech Lessons Learned From JPM 2012

1/13/2012 by TheStreet.com

Geron looking to sell stem cell therapy, Bloomberg reports

1/11/2012 by Theflyonthewall.com

Geron hired Stifel Nicolaus to sell stem cell assets, Bloomberg reports

1/11/2012 by Theflyonthewall.com
See More Articles...